{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-011904","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2023-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.415823+00:00","generated_at":"2026-06-13T07:51:34.862529+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Virios announces positive Long-COVID data for valacyclovir/celecoxib; cash $4.5M","bullets":["Female long-COVID patients showed significant improvements in fatigue, pain, and autonomic dysfunction after 14 weeks of Val/Cel vs routine care.","Company plans to meet with FDA in H2 2023 to discuss opening an IND for formal PASC treatment assessment.","Treatment well tolerated; no serious adverse events; nausea most common AE in Val/Cel group.","As of June 30, 2023, Virios had approximately $4.5M in cash and cash equivalents."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-011904","json":"https://secwatch.observer/filing/0001558370-23-011904.json","markdown":"https://secwatch.observer/filing/0001558370-23-011904.md","text":"https://secwatch.observer/filing/0001558370-23-011904.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000155837023011904/0001558370-23-011904-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000155837023011904/tmb-20230714x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T07:51:34.862529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}